article · Future Medicinal Chemistry
<b>Aim:</b> This study focused on designing and synthesizing novel derivatives of 3,5,8-trisubstituted coumarin. <b>Results:</b> The synthesized compounds, particularly compound <b>5</b>, exhibited significant cytotoxic effects on MCF-7 cells, surpassing staurosporine, and reduced toxicity toward MCF-10A cells, highlighting potential pharmacological advantages. Further, compound <b>5</b> altered the cell cycle and significantly increased apoptosis in MCF-7 cells, involving both early (41.7-fold) and late stages (33-fold), while moderately affecting necrotic signaling. The antitumor activity was linked to a notable reduction (4.78-fold) in topoisomerase IIβ expression. Molecular modeling indicated compound <b>5</b>'s strong affinity for EGFR, human EGF2 and topoisomerase II proteins. <b>Conclusion:</b> These findings highlight compound <b>5</b> as a multifaceted antitumor agent for breast cancer.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4155/fmc-2023-0375
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.